These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19033369)

  • 61. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys.
    Hara T; Araki H; Kusaka M; Harada M; Cho N; Suzuki N; Furuya S; Fujino M
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1697-704. PubMed ID: 12679460
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 63. GnRH Antagonists with or without Add-Back Therapy: A New Alternative in the Management of Endometriosis?
    Donnez J; Dolmans MM
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768770
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
    MacLean DB; Shi H; Faessel HM; Saad F
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4579-87. PubMed ID: 26502357
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of RU16117, an orally active weak oestrogenic compound, in postmenopausal women.
    Faure N; Labrie F; Olivier G; Tremblay M; Cloutier D; Lemay A; Ferland L; Azadian-Boulanger G; Bouton MM; Husson JM; Raynaud JP
    Maturitas; 1980 Jul; 2(2):155-68. PubMed ID: 6782429
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Does timing matter when initiating elagolix in a natural menstrual cycle?
    Danis RB; Sriprasert I; Stanczyk FZ; Paulson RJ; Winer SA; Ho JR
    F S Rep; 2021 Sep; 2(3):308-313. PubMed ID: 34553156
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
    Leroy I; d'Acremont M; Brailly-Tabard S; Frydman R; de Mouzon J; Bouchard P
    Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).
    Nelson LR; Fujimoto VY; Jaffe RB; Monroe SE
    Fertil Steril; 1995 May; 63(5):963-9. PubMed ID: 7536693
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA; Brenner PF; Kletzky OA; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study.
    Li X; Sun F; Zhang X; Lin P; Shen K; Shen Y; Ma L; Cao Y; Wang C
    BMC Med; 2023 Apr; 21(1):129. PubMed ID: 37013610
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Scheduling GnRH antagonist cycles by a short course of oral estradiol administration during early follicular phase: a comparative study with non-scheduled cycles.
    Aslan K; Avci B; Uncu G; Saribal S; Ata B
    Gynecol Endocrinol; 2015 Jun; 31(6):465-8. PubMed ID: 25982362
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men.
    Finkelstein JS; Whitcomb RW; O'Dea LS; Longcope C; Schoenfeld DA; Crowley WF
    J Clin Endocrinol Metab; 1991 Sep; 73(3):609-20. PubMed ID: 1908484
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
    D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
    Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers.
    Oberyé JJ; Mannaerts BM; Huisman JA; Timmer CJ
    Fertil Steril; 1999 Dec; 72(6):1006-12. PubMed ID: 10593372
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiovulatory doses of antagonists of LH-RH inhibit LH and progesterone but not FSH and estradiol release.
    Kovács M; Koppán M; Mezö I; Teplán I; Flerkó B
    J Neuroendocrinol; 1993 Dec; 5(6):603-8. PubMed ID: 8680431
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men.
    Yuen F; Thirumalai A; Pham C; Swerdloff RS; Anawalt BD; Liu PY; Amory JK; Bremner WJ; Dart C; Wu H; Hull L; Blithe DL; Long J; Wang C; Page ST
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e835-47. PubMed ID: 31976519
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.
    Pokrzywinski RM; Soliman AM; Chen J; Snabes MC; Coyne KS; Surrey ES; Taylor HS
    Am J Obstet Gynecol; 2020 Jun; 222(6):592.e1-592.e10. PubMed ID: 31759891
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Endocrine profiles and gonadotropin response to Gn-RH of men with testicular cancer].
    Watanabe M; Fuji K; Suzuki K; Kitamura T; Okumura D; Kasahara T; Igarashi T; Masuyama T; Hiramori T; Higaki M; Yoshida H
    Nihon Hinyokika Gakkai Zasshi; 2003 Jul; 94(5):543-50. PubMed ID: 12910930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.